Fig. 2
FASN inhibition sensitizes to MAPKi therapy. a Fraction.13C glucose incorporation into palmitate in D10 BMR cells (n = 3) following DT and TVB-3664 treatment. One-way ANOVA with Tukey’s multiple comparisons. b-c Real time cell growth analysis of 451lu R and D10 BMR cells following MAPKi and TVB-3664 treatment in 2D (n = 3) and 3D (n = 12) spheroid cultures. One-way ANOVA with Tukey’s multiple comparisons. d Real time cell growth analysis of D10 BMR cells (n = 6) following DT treatment and siRNA-mediated knockdown of FASN. One-way ANOVA with Tukey’s multiple comparisons. e Tumor growth curves of Mel006 PDX bearing mice treated with vehicle, TVB-3664, dabrafenib, or the combination. One-way ANOVA with Tukey’s multiple comparisons. f Ki67 staining of Mel006 PDX bearing mice treated with vehicle, TVB-3664, dabrafenib, or the combination. One-way ANOVA with Tukey’s multiple comparisons. g Real time cell growth analysis of 451lu R cells (n = 4) following MAPKi and TVB-3664 treatment with medium refresh (without treatment) at indicated timepoint. Data represent mean ± SEM of biologically independent samples. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001)